Psychedelics like psilocybin, MDMA, and ketamine are emerging as promising therapeutic tools for mental health issues. Here's ...

FDA supports CaaMTech's CT-4201 psilocin program for depression, advancing psychedelic therapy and clearing key regulatory ...

Phase 2b clinical trial of GH001 in patients with treatment-resistant depression completed enrolment of the double-blind phase in Q3 2024Phase 1 ...

People suffering from major depressive disorder (MDD) and treatment-resistant depression (TRD) often face challenging ...

Phase 2b clinical trial of GH001 in patients with treatment-resistant depression completed enrolment of the double-blind phase in Q3 2024 Phase 1 clinical trial to evaluate proprietary aerosol ...

SALT LAKE CITY, Utah. (Ivanhoe Newswire) - Chronic pain and treatment-resistant depression both impact millions of people. Both can be debilitating and both can leave people feeling hopeless, ...

The researchers found that depending on how strictly medical providers apply safety criteria, between 24% and 62% of patients ...

Psilocybin-assisted therapy could potentially benefit up to 5.6 million Americans with major depressive disorder or treatment ...

A new study has demonstrated the potential impact of psilocybin-assisted therapy on people with depression, if approved by ...

Chronic pain and treatment resistant depression — both impact millions of people, both can be debilitating, and both can leave people feeling hopeless, impacting daily activities, relationships, and ...

The company is set to begin Phase 2 trials for VLS-01 in treatment-resistant depression and EMP-01 for social anxiety disorder by the end of 2024. With FDA clearance for VLS-01 and a strategic ...

Patients with treatment-resistant depression often try a variety of medications and therapies without any success, which can ...